Sexual dysfunction and cardiac risk (The Second Princeton Consensus Conference)

John B. Kostis, Graham Jackson, Raymond Rosen, Elizabeth Barrett-Connor, Kevin Billups, Arthur L. Burnett, Culley Carson, Melvin Cheitlin, Robert Debusk, Vivian Fonseca, Peter Ganz, Irwin Goldstein, Andre Guay, Dimitris Hatzichristou, Judd E. Hollander, Adolph Hutter, Stuart Katz, Robert A. Kloner, Murray Mittleman, Francesco MontorsiPiero Montorsi, Ajay Nehra, Richard Sadovsky, Ridwan Shabsigh

Research output: Contribution to journalArticle

168 Citations (Scopus)

Abstract

Recent studies have highlighted the relation between erectile dysfunction (ED) and cardiovascular disease. In particular, the role of endothelial dysfunction and nitric oxide in ED and atherosclerotic disease has been elucidated. Given the large number of men receiving medical treatment for ED, concerns regarding the risk for sexual activity triggering acute cardiovascular events and potential risks of adverse or unanticipated drug interactions need to be addressed. A risk stratification algorithm was developed by the First Princeton Consensus Panel to evaluate the degree of cardiovascular risk associated with sexual activity for men with varying degrees of cardiovascular disease. Patients were assigned to 3 categories: low, intermediate (including those requiring further evaluation), and high risk. This consensus study from the Second Princeton Consensus Conference corroborates and clarifies the algorithm and emphasizes the importance of risk factor evaluation and management for all patients with ED. The panel reviewed recent safety and drug interaction data for 3 phosphodiesterase (PDE)-5 inhibitors (sildenafil, tadalafil, vardenafil), with emphasis on the safety of these agents in men with ED and concomitant cardiovascular disease. Increasing evidence supports the role of lifestyle intervention in ED, specifically weight loss and increased physical activity, particularly in patients with ED and concomitant cardiovascular disease. Special management recommendations for patients taking PDE-5 inhibitors who present at the emergency department and other emergency medical situations are described. Finally, further research on the role of PDE-5 inhibition in treating patients with other medical or cardiovascular disorders is recommended.

Original languageEnglish
JournalThe American Journal of Cardiology
Volume96
Issue number12 SUPPL. 2
DOIs
Publication statusPublished - Dec 26 2005

Fingerprint

Erectile Dysfunction
Consensus
Cardiovascular Diseases
Phosphodiesterase 5 Inhibitors
Drug Interactions
Sexual Behavior
Type 5 Cyclic Nucleotide Phosphodiesterases
Safety
Risk Management
Life Style
Hospital Emergency Service
Weight Loss
Nitric Oxide
Emergencies
Exercise
Research

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Kostis, J. B., Jackson, G., Rosen, R., Barrett-Connor, E., Billups, K., Burnett, A. L., ... Shabsigh, R. (2005). Sexual dysfunction and cardiac risk (The Second Princeton Consensus Conference). The American Journal of Cardiology, 96(12 SUPPL. 2). https://doi.org/10.1016/j.amjcard.2005.12.018

Sexual dysfunction and cardiac risk (The Second Princeton Consensus Conference). / Kostis, John B.; Jackson, Graham; Rosen, Raymond; Barrett-Connor, Elizabeth; Billups, Kevin; Burnett, Arthur L.; Carson, Culley; Cheitlin, Melvin; Debusk, Robert; Fonseca, Vivian; Ganz, Peter; Goldstein, Irwin; Guay, Andre; Hatzichristou, Dimitris; Hollander, Judd E.; Hutter, Adolph; Katz, Stuart; Kloner, Robert A.; Mittleman, Murray; Montorsi, Francesco; Montorsi, Piero; Nehra, Ajay; Sadovsky, Richard; Shabsigh, Ridwan.

In: The American Journal of Cardiology, Vol. 96, No. 12 SUPPL. 2, 26.12.2005.

Research output: Contribution to journalArticle

Kostis, JB, Jackson, G, Rosen, R, Barrett-Connor, E, Billups, K, Burnett, AL, Carson, C, Cheitlin, M, Debusk, R, Fonseca, V, Ganz, P, Goldstein, I, Guay, A, Hatzichristou, D, Hollander, JE, Hutter, A, Katz, S, Kloner, RA, Mittleman, M, Montorsi, F, Montorsi, P, Nehra, A, Sadovsky, R & Shabsigh, R 2005, 'Sexual dysfunction and cardiac risk (The Second Princeton Consensus Conference)', The American Journal of Cardiology, vol. 96, no. 12 SUPPL. 2. https://doi.org/10.1016/j.amjcard.2005.12.018
Kostis JB, Jackson G, Rosen R, Barrett-Connor E, Billups K, Burnett AL et al. Sexual dysfunction and cardiac risk (The Second Princeton Consensus Conference). The American Journal of Cardiology. 2005 Dec 26;96(12 SUPPL. 2). https://doi.org/10.1016/j.amjcard.2005.12.018
Kostis, John B. ; Jackson, Graham ; Rosen, Raymond ; Barrett-Connor, Elizabeth ; Billups, Kevin ; Burnett, Arthur L. ; Carson, Culley ; Cheitlin, Melvin ; Debusk, Robert ; Fonseca, Vivian ; Ganz, Peter ; Goldstein, Irwin ; Guay, Andre ; Hatzichristou, Dimitris ; Hollander, Judd E. ; Hutter, Adolph ; Katz, Stuart ; Kloner, Robert A. ; Mittleman, Murray ; Montorsi, Francesco ; Montorsi, Piero ; Nehra, Ajay ; Sadovsky, Richard ; Shabsigh, Ridwan. / Sexual dysfunction and cardiac risk (The Second Princeton Consensus Conference). In: The American Journal of Cardiology. 2005 ; Vol. 96, No. 12 SUPPL. 2.
@article{13994c9e8f8c408db95390e703538246,
title = "Sexual dysfunction and cardiac risk (The Second Princeton Consensus Conference)",
abstract = "Recent studies have highlighted the relation between erectile dysfunction (ED) and cardiovascular disease. In particular, the role of endothelial dysfunction and nitric oxide in ED and atherosclerotic disease has been elucidated. Given the large number of men receiving medical treatment for ED, concerns regarding the risk for sexual activity triggering acute cardiovascular events and potential risks of adverse or unanticipated drug interactions need to be addressed. A risk stratification algorithm was developed by the First Princeton Consensus Panel to evaluate the degree of cardiovascular risk associated with sexual activity for men with varying degrees of cardiovascular disease. Patients were assigned to 3 categories: low, intermediate (including those requiring further evaluation), and high risk. This consensus study from the Second Princeton Consensus Conference corroborates and clarifies the algorithm and emphasizes the importance of risk factor evaluation and management for all patients with ED. The panel reviewed recent safety and drug interaction data for 3 phosphodiesterase (PDE)-5 inhibitors (sildenafil, tadalafil, vardenafil), with emphasis on the safety of these agents in men with ED and concomitant cardiovascular disease. Increasing evidence supports the role of lifestyle intervention in ED, specifically weight loss and increased physical activity, particularly in patients with ED and concomitant cardiovascular disease. Special management recommendations for patients taking PDE-5 inhibitors who present at the emergency department and other emergency medical situations are described. Finally, further research on the role of PDE-5 inhibition in treating patients with other medical or cardiovascular disorders is recommended.",
author = "Kostis, {John B.} and Graham Jackson and Raymond Rosen and Elizabeth Barrett-Connor and Kevin Billups and Burnett, {Arthur L.} and Culley Carson and Melvin Cheitlin and Robert Debusk and Vivian Fonseca and Peter Ganz and Irwin Goldstein and Andre Guay and Dimitris Hatzichristou and Hollander, {Judd E.} and Adolph Hutter and Stuart Katz and Kloner, {Robert A.} and Murray Mittleman and Francesco Montorsi and Piero Montorsi and Ajay Nehra and Richard Sadovsky and Ridwan Shabsigh",
year = "2005",
month = "12",
day = "26",
doi = "10.1016/j.amjcard.2005.12.018",
language = "English",
volume = "96",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "12 SUPPL. 2",

}

TY - JOUR

T1 - Sexual dysfunction and cardiac risk (The Second Princeton Consensus Conference)

AU - Kostis, John B.

AU - Jackson, Graham

AU - Rosen, Raymond

AU - Barrett-Connor, Elizabeth

AU - Billups, Kevin

AU - Burnett, Arthur L.

AU - Carson, Culley

AU - Cheitlin, Melvin

AU - Debusk, Robert

AU - Fonseca, Vivian

AU - Ganz, Peter

AU - Goldstein, Irwin

AU - Guay, Andre

AU - Hatzichristou, Dimitris

AU - Hollander, Judd E.

AU - Hutter, Adolph

AU - Katz, Stuart

AU - Kloner, Robert A.

AU - Mittleman, Murray

AU - Montorsi, Francesco

AU - Montorsi, Piero

AU - Nehra, Ajay

AU - Sadovsky, Richard

AU - Shabsigh, Ridwan

PY - 2005/12/26

Y1 - 2005/12/26

N2 - Recent studies have highlighted the relation between erectile dysfunction (ED) and cardiovascular disease. In particular, the role of endothelial dysfunction and nitric oxide in ED and atherosclerotic disease has been elucidated. Given the large number of men receiving medical treatment for ED, concerns regarding the risk for sexual activity triggering acute cardiovascular events and potential risks of adverse or unanticipated drug interactions need to be addressed. A risk stratification algorithm was developed by the First Princeton Consensus Panel to evaluate the degree of cardiovascular risk associated with sexual activity for men with varying degrees of cardiovascular disease. Patients were assigned to 3 categories: low, intermediate (including those requiring further evaluation), and high risk. This consensus study from the Second Princeton Consensus Conference corroborates and clarifies the algorithm and emphasizes the importance of risk factor evaluation and management for all patients with ED. The panel reviewed recent safety and drug interaction data for 3 phosphodiesterase (PDE)-5 inhibitors (sildenafil, tadalafil, vardenafil), with emphasis on the safety of these agents in men with ED and concomitant cardiovascular disease. Increasing evidence supports the role of lifestyle intervention in ED, specifically weight loss and increased physical activity, particularly in patients with ED and concomitant cardiovascular disease. Special management recommendations for patients taking PDE-5 inhibitors who present at the emergency department and other emergency medical situations are described. Finally, further research on the role of PDE-5 inhibition in treating patients with other medical or cardiovascular disorders is recommended.

AB - Recent studies have highlighted the relation between erectile dysfunction (ED) and cardiovascular disease. In particular, the role of endothelial dysfunction and nitric oxide in ED and atherosclerotic disease has been elucidated. Given the large number of men receiving medical treatment for ED, concerns regarding the risk for sexual activity triggering acute cardiovascular events and potential risks of adverse or unanticipated drug interactions need to be addressed. A risk stratification algorithm was developed by the First Princeton Consensus Panel to evaluate the degree of cardiovascular risk associated with sexual activity for men with varying degrees of cardiovascular disease. Patients were assigned to 3 categories: low, intermediate (including those requiring further evaluation), and high risk. This consensus study from the Second Princeton Consensus Conference corroborates and clarifies the algorithm and emphasizes the importance of risk factor evaluation and management for all patients with ED. The panel reviewed recent safety and drug interaction data for 3 phosphodiesterase (PDE)-5 inhibitors (sildenafil, tadalafil, vardenafil), with emphasis on the safety of these agents in men with ED and concomitant cardiovascular disease. Increasing evidence supports the role of lifestyle intervention in ED, specifically weight loss and increased physical activity, particularly in patients with ED and concomitant cardiovascular disease. Special management recommendations for patients taking PDE-5 inhibitors who present at the emergency department and other emergency medical situations are described. Finally, further research on the role of PDE-5 inhibition in treating patients with other medical or cardiovascular disorders is recommended.

UR - http://www.scopus.com/inward/record.url?scp=29544443156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29544443156&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2005.12.018

DO - 10.1016/j.amjcard.2005.12.018

M3 - Article

C2 - 16387575

AN - SCOPUS:29544443156

VL - 96

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 12 SUPPL. 2

ER -